Premier Alternatives

CORXEL Pharmaceuticals

Drug Discovery · Shanghai, China · Founded 2019 · Privately Held (backing)

Developer of small molecule cardiac myosin inhibitor drug treatments designed for the treatment of hypertrophic cardiomyopathy, in-licensed from Cytokinetics. CORXEL Pharmaceuticals is based in Shanghai, China and was founded in 2019. Its last reported valuation was $475 million in Sep 2024. It has raised $452 million across 1 recorded round; the latest was a $287 million Series D1 in Jan 2026.

Last reported valuation
$474.9M
Oct 2026
Priced at
—
Total raised
$451.8M
Last round
Later Stage VC (Series D1)
Jan 2026

CORXEL Pharmaceuticals key facts

as of Oct 2026
  • Developer of small molecule cardiac myosin inhibitor drug treatments designed for the treatment of hypertrophic cardiomyopathy, in-licensed from Cytokinetics.
  • CORXEL Pharmaceuticals is valued at approximately $474.9M as of Oct 2026 (last reported valuation).
  • It has raised $451.8M across 1 recorded rounds; the latest was Later Stage VC (Series D1) ($287.0M) in Jan 2026.
  • Notable investors include RA Capital Management, New Enterprise Associates, The Invus Group, SR One Capital Management, RTW Investments — 13 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$474.9M

CORXEL Pharmaceuticals's last reported valuation, Sep 2024. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of CORXEL Pharmaceuticals with a free account
  • ·The complete investor list: 13 names
  • ·Watch CORXEL Pharmaceuticals: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

CORXEL Pharmaceuticals funding rounds

1 rounds
Jan 2026Later Stage VC (Series D1)$287.0M▮
Full funding history →

CORXEL Pharmaceuticals valuation

CORXEL Pharmaceuticals's last reported valuation was $475 million in Sep 2024. No priced round, secondary trade or fund mark has surfaced since.

How much has CORXEL Pharmaceuticals raised?

CORXEL Pharmaceuticals has raised $452 million in total; 1 of its rounds is on record. The largest on record was a $287 million Series D1 in Jan 2026.

CORXEL Pharmaceuticals investors

13 investors are on record for CORXEL Pharmaceuticals, including RA Capital Management, New Enterprise Associates, The Invus Group and SR One Capital Management. By type, the record holds 3 hedge funds, 1 venture capital firm and 1 asset manager. The Series D1 in Jan 2026 drew 9 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Rivus Pharmaceuticals ($489 million), Electra Therapeutics ($479 million) and Diagonal Therapeutics ($459 million).

About CORXEL Pharmaceuticals

Developer of small molecule cardiac myosin inhibitor drug treatments designed for the treatment of hypertrophic cardiomyopathy, in-licensed from Cytokinetics. The company offers first-class treatments to Chinese cardiovascular and ophthalmology patients and treats patients suffering from serious life-threatening health diseases, thereby enabling biotechnology companies to respond to unmet medical needs in the fields of cardiovascular and ophthalmology diseases.

Industry
Drug Discovery
Sector
Healthcare
HQ
Shanghai, China
Founded
2019
Employees
45
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.